Transplant Institute

Beth Israel Deaconess Medical Center

A teaching hospital of Harvard Medical School

LIVER RECIPIENT POST TRANSPLANT CLINICAL PATHWAY

This Clinical Pathway is intended to assist in clinical decision making by describing a range of generally acceptable interventions and outcomes. The guidelines attempt to define practices that meet the needs of most patients under most circumstances. However, the ultimate judgment must be made based on circumstances that are relevant to that patient and treatment may be modified according to the individual patient needs.

		Discharge to 2 months post transplant							2-3 Months				3-5 Months			6 Months-12 Months	Year 1	Years 2+
		1WK	2WK	3WK	4WK	5WK	6WK	7WK	8WK	9WK	10WK	11WK	3 Month	4 Month	5 Month			
	Date:																	
VISITS	Surgeon	X	X	X	X	X	X	X	X		X		X	X	X	PRN	PRN	q 3-6 Months
	Hepatologist	PRN	PRN	PRN	X	PRN	PRN	PRN	X		PRN		X	PRN	PRN	Monthly	X	q 3-6 Months
	Transplant Coordinator	X	X	X	X	X	X	X	X	PRN	X	PRN	X	X	X	Monthly	X	PRN
	Research Coordinator	X	PRN	PRN	PRN	PRN	PRN	PRN	PRN	PRN	PRN	PRN	PRN	PRN	PRN	PRN	X	PRN
	Transplant Pharmacist	X	PRN	PRN	X	PRN	PRN	PRN	PRN	PRN	PRN	PRN	X	PRN	PRN	PRN	PRN	PRN
	Dietician	X	PRN	PRN	X													
	Behavioral Health				X								X			Month 6 only	X	q 1 Year
	PCP												X			Month 6 only	X	PRN
	Dermatology																X	q 1 Year
LETTERS	PCP, referring MD and hepatologist, other MDs	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
LAB TESTS	CBC, Diff	X2	X2	X2	X2	X2	X2	X2	X2	X2	X2	X2	q 1wk	q 1wk	q 1wk	Monthly	X	Monthly
	PT/INR	X2	X2	X2	X2	X2	X2	X2										
	Renal & liver profile	X2	X2	X2	X2	X2	X2	X2	X2	X2	X2	X2	q 1wk	q 1wk	q 1wk	Monthly	X	Monthly
	Drug levels	X2	X2	X2	X2	X2	X2	X2	X2	X2	X2	X2	q 1wk	q 1wk	q 1wk	Monthly	X	Monthly
	Bone Mineral Density																X	q 2 Years
	CMV D+/R- monitoring:																	
	○ CMV PCR q2wks until IgG positive															Month 6 only	X	
	○ CMV IgG q4wks until IgG positive															Month 6 only	X	
MEDICATIONS	Stop Valganciclovir unless CMV D+/R-												X					
	Stop Valganciclovir and initiate monitoring															Month 6 only		
TESTS FOR HEPATIC MALIGNANCY	AFP Screening	X			X								X			Month 6 only	X	q 1 Year
	CT thorax & abdomen												X			Month 6 only	X	Annually for 2 years if Milan Criteria or annually for 3 years if outside Milan Criteria
TESTS FOR LIVE DONOR RECIPIENTS	Duplex US				X								X			Month 6 only	X	
	CT with liver volume calculation				X								X					
TESTS FOR PSC RECIPIENTS	Colonoscopy with multiple random biopsies for dysplasia																X	q 1 Year
TESTS FOR HBV	Quant anti-HBsAb	X	X	X	X	X	X	X	X	X	X	X	X	X	X	Monthly	X	q 3 Months
	HBV DNA												X			q 3 Months	X	q 3 Months
	HBsAg				X				X				X			q 3 Months	X	q 3 Months
TESTS FOR HCV	HCV RNA												X			q 3 Months		q 3 Months
	Liver biopsy												X			Month 6 only	X	q 1 Year

Development supported by the Julie Henry Fund

© 2006 Beth Israel Deaconess Medical Center, Inc.
Reproduction without authorization is prohibited

Contact BIDMC Transplant Institute at www.bidmc.org/transplantcare for further information

Rev. 5/27/10